logo BDSP

Base documentaire

  1. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.

    Article - En anglais

    More than $100 billion is spent in the United States each year on cardiovascular disease, primarily for hospitalizations and revascularization procedures.

    This is more than for any other disease state.

    As the clinical practice of medicine shifts from the paradigm of private practice to the managed care environment, cost-effectiveness is becoming increasingly important.

    A primary measure in analyzing cost-effectiveness is the cost-effectiveness ratio, or the dollar cost per unit of improvement for a given expenditure.

    This measure allows healthcare planners to compare completely different interventions.

    With approximately 52 million adult U.S. citizens having elevated low-density lipoprotein (LDL) cholesterol levels, lipid-lowering therapy-with diet or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors-is an important consideration for primary care physicians and managed care providers.

    The National Health and Nutrition Examination Survey (NHANES) III indicates that 75-88% of adults who have coronary artery disease (CAD) risk factors or CAD require only a moderate (20-30%) reduction in LDL cholesterol levels to reach National Cholesterol Education Program goals.

    The clinical literature shows that all 4 of the currently available HMG-CoA reductase inhibitors can provide appropriate, moderate LDL cholesterol reductions within their recommended dosage ranges. (...)

    Mots-clés Pascal : Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Inhibiteur enzyme, Cholestérol LDL, Analyse coût efficacité, Economie santé, Chimiothérapie, Traitement, Homme, Etude comparative, Hypolipémiant

    Mots-clés Pascal anglais : Hydroxymethylglutaryl-CoA synthase, Oxo-acid-lyases, Carbon-carbon lyases, Lyases, Enzyme, Enzyme inhibitor, Cholesterol LDL, Cost efficiency analysis, Health economy, Chemotherapy, Treatment, Human, Comparative study, Antilipemic agent

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0013564

    Code Inist : 002B02N. Création : 21/05/1997.